- Conditions
- Healthy Volunteers
- Interventions
- TAK-935, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2401–2424
of 7,074
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Hepatitis C, Hepatitis C Virus (HCV) Infection
- Interventions
- ABT-267, Pegylated interferon (pegIFN), Ribavirin (RBV), Placebo for ABT-267
- Drug · Other
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 7 more
- Conditions
- Fibromyalgia
- Interventions
- NYX-2925, Placebo oral capsule
- Drug
- Lead sponsor
- Aptinyx
- Industry
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Cincinnati, Ohio
- Conditions
- Cystic Fibrosis
- Interventions
- VX-661, Ivacaftor, Placebo matched to VX-661, Placebo matched to ivacaftor
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Oakland, California • Boise, Idaho + 16 more
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- Linaclotide, Matching Placebo
- Drug
- Lead sponsor
- Ironwood Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 95
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 81 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Bexagliflozin, Placebo
- Drug
- Lead sponsor
- Theracos
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 66
- States / cities
- Gilbert, Arizona • Little Rock, Arkansas • Azusa, California + 57 more
- Conditions
- Tardive Dyskinesia
- Interventions
- NBI-1065890, Placebo
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 31
- States / cities
- Bryant, Arkansas • Chino, California • Fountain Valley, California + 27 more
- Conditions
- Sinusitis
- Interventions
- Reslizumab, Placebo
- Drug
- Lead sponsor
- Joshua S. Jacobs
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Walnut Creek, California
- Conditions
- Schizophrenia
- Interventions
- Placebo, Bitopertin, Antipsychotics
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 625 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 27
- States / cities
- Costa Mesa, California • Escondido, California • Granada Hills, California + 24 more
- Conditions
- Nicotine Addiction, Craving
- Interventions
- Varenicline Tartrate, Placebo
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Autism Spectrum Disorder
- Interventions
- Cannabidivarin, Matched Placebo
- Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 2
- States / cities
- New York, New York • The Bronx, New York
- Conditions
- Peanut Allergy
- Interventions
- AR101, Placebo
- Biological
- Lead sponsor
- Aimmune Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 506 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 50 more
- Conditions
- Atopic Dermatitis
- Interventions
- SAR444656 (KT-474), Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Boynton Beach, Florida • Doral, Florida • Hollywood, Florida + 4 more
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Cytarabine, Idasanutlin, Placebo
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 7
- States / cities
- Great Neck, New York • Hawthorne, New York • New York, New York + 3 more
- Conditions
- Functional Constipation
- Interventions
- Linaclotide, Placebo
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 2 Years to 5 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 15 more
- Conditions
- Healthy Volunteers
- Interventions
- TAK-988, TAK-988 Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Glendale, California • Millcreek, Utah
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 15
- States / cities
- Fullerton, California • Orange City, Florida • Tampa, Florida + 12 more
- Conditions
- Chronic Heart Failure
- Interventions
- JTT-861 Capsules, Placebo Capsules
- Drug
- Lead sponsor
- Shionogi Inc.
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Crystal River, Florida • Hialeah, Florida + 16 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Garadacimab, Placebo
- Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 19 more
- Conditions
- Obesity
- Interventions
- Canagliflozin, Phentermine, Matching Placebo to Canagliflozin, Matching Placebo to Phentermine
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 335 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Walnut Creek, California • Jacksonville, Florida + 14 more
- Conditions
- Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
- Interventions
- Galvokimig, Placebo
- Biological
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 16
- States / cities
- Encino, California • Westminster, California • Miami, Florida + 13 more
- Conditions
- Smoking Cessation, Nicotine Dependence
- Interventions
- Nicotine Replacement Treatment (NRT), varenicline, Behavioral counseling for smoking cessation
- Drug · Behavioral
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, CIPN - Chemotherapy-Induced Peripheral Neuropathy
- Interventions
- High Concentration Capsaicin Patch (HCCP), Placebo patch
- Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Demyelinating Diseases, Demyelination; Corpus Callosum, Multiple Sclerosis Brain Lesion, Multiple Sclerosis Acute and Progressive, Clinically Isolated Syndrome, CNS Demyelinating
- Interventions
- Clemastine Fumarate, Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California